Biogen executives fend off Alzheimer's questions with pipeline promises, deal talk

29th January 2019 Uncategorised 0

Biogen keeps its Alzheimer’s trial results close to the vest, a habit that annoys many Wall Street analysts, and those analysts didn’t get more answers than usual Tuesday. But Biogen executives maintained their pipeline isn’t just about Alzheimer’s—and deal-making is definitely on the table.

More: Biogen executives fend off Alzheimer's questions with pipeline promises, deal talk
Source: fierce